Human and Vet Focus Tri-Source Pharma operates at the intersection of human and animal health, specializing in oncology, sedation, and pain management. This cross‑over positioning suggests sales opportunities to provide shared formulations, cross‑species trials support, and co‑marketing potential for therapies with cross‑over potential.

Mid‑Market Scale With 11‑50 employees and revenue in the 1M‑10M range, there is potential to pursue partnerships that offer scalable manufacturing, contract development and manufacturing services, and accelerated onboarding for niche therapies in both human and veterinary portfolios.

Regulatory Leverage The focus on FDA and CVM‑approved therapies signals readiness to pursue partnerships for commercialization, distribution, and regulatory consulting support, enabling faster market access and expanded geographies for approved oncology, sedation, and pain management products.

Tech‑Enabled Ops Existing tech stack including WordPress, Google Cloud, Microsoft 365, and ASP.NET indicates capability to support streamlined digital marketing, eCommerce presence, and secure collaboration with partners, potentially lowering customer acquisition and onboarding costs.

Growth Through Subsidiaries Links to NextSource Pharma and IVAO ES imply a multi‑subsidiary structure focused on broader health care solutions, presenting sales opportunities to bundle offerings, cross‑sell across subsidiaries, and leverage shared distribution channels for human and animal health products.